Menus Subscribe Search

Follow us


injection-needle

(PHOTO: JOLOEI/SHUTTERSTOCK)

The Cheaper, Bacteria-Derived Future of Drugs

• July 19, 2013 • 6:00 AM

(PHOTO: JOLOEI/SHUTTERSTOCK)

Drugs made from plants are often too expensive for the people who need them. A group of scientists may have found a solution.

The world is in dire need of cheap drugs to combat malaria. Malaria may seem like a disease from the distant past, but world-wide, it still exacts a large toll. Even worse, today’s malaria parasites are often resistant to the standard anti-malarial drugs. Newer and more effective drugs exist, but these drugs are well out of the price range of the patients in the developing world who need them.

Part of the problem is that the newer anti-malarial drugs come from plants. For thousands of years, humans have been getting their drugs from plants. While plants make a wide range of pharmacologically active compounds, they are not very practical: they can be difficult to cultivate in large quantities, their chemical yield can be unreliable, and the product we’re interested in can be expensive to isolate from other chemicals made by the plant. Add all that up and plant-derived drugs are too expensive for the people who need them. But there may be a solution: drugs made from bacteria (and other microbes).

Different versions of the same class of enzyme can carry out a mind-boggling range of chemical reactions.

The current source of newer anti-malarial drugs is Sweet Wormwood, a plant used in traditional Chinese medicine. The Chinese have long cultivated Sweet Wormwood, but the current world acreage of this plant is much less than we need. And even if there were enough Sweet Wormwood available, extracting the active ingredient, artemisinin, is an expensive and inefficient process.

To tackle this problem, the Bill and Melinda Gates Foundation funded a California-based group of industry and academic scientists to build a microbe that can crank out suitably large amounts of artemisinin (or artemisinic acid, a closely related chemical) while fermenting in an industrial-scale vat. The group recently reported success, which they achieved by making a variety of genetic modifications to ordinary baker’s yeast. The result is a yeast that makes artemisinic acid while fermenting sugar.

In the case of artemisinin-producing yeast, the researchers modified a natural yeast metabolic system, one that converts a chemical called Acetyl-CoA into a steroid. Acetyl-CoA is made by every organism on Earth, and is a precursor of many important biological molecules. The scientists made several genetic hacks to this metabolic system, resulting in a yeast strain whose enzyme levels can be fine-tuned by adding cheap chemicals to the yeasts’ nutrient broth. With the enzyme levels set just right, the yeasts’ Acetyl-CoA-to-steroid machinery gets highjacked to make large amounts of a chemical that is just a few enzymatic steps away from artemisinic acid.

The final genetic modification was to build in new enzymes that finish the job of making artemisinic acid. To do this, the researchers took a set of enzyme genes from Sweet Wormwood and transplanted them into the genome of their engineered yeast strain. The result: a yeast that feeds on sugar and pumps out artemisinic acid, at a fraction of the cost of extracting artemisinin from hectares of Sweet Wormwood.

The project involved substantial R&D, but principles can apply broadly. One reason why this kind of Wormwood-to-yeast metabolic engineering is successful is that the Wormwood enzymes involved are not very different from yeast enzymes that have other functions, making it possible for Wormwood enzymes to function in a yeast cell. In nature, there are many variations on a basic enzyme design; different versions of the same class of enzyme can carry out a mind-boggling range of chemical reactions. There is even a strain of bacteria (which evolved naturally in a contaminated military training range) whose enzymes break down explosives for food. The chemical repertoire of the natural world is tremendous. By harnessing that repertoire in microbial factories, we can make drugs, biofuels, and other chemicals in a way that has the potential to be cheaper, safer, and less damaging to the environment.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 31 • 12:00 PM

In the Picture: SNAP Food Benefits, Birthday Cake, and Walmart

In every issue, we fix our gaze on an everyday photograph and chase down facts about details in the frame.


October 31 • 10:15 AM

Levels of Depression Could Be Evaluated Through Measurements of Acoustic Speech

Engineers find tell-tale signs in speech patterns of the depressed.


October 31 • 8:00 AM

Who Wants a Cute Congressman?

You probably do—even if you won’t admit it. In politics, looks aren’t everything, but they’re definitely something.


October 31 • 7:00 AM

Why Scientists Make Promises They Can’t Keep

A research proposal that is totally upfront about the uncertainty of the scientific process and its potential benefits might never pass governmental muster.


October 31 • 6:12 AM

The Psychology of a Horror Movie Fan

Scientists have tried to figure out the appeal of axe murderers and creepy dolls, but it mostly remains a spooky mystery.


October 31 • 4:00 AM

The Power of Third Person Plural on Support for Public Policies

Researchers find citizens react differently to policy proposals when they’re framed as impacting “people,” as opposed to “you.”


October 30 • 4:00 PM

I Should Have Told My High School Students About My Struggle With Drinking

As a teacher, my students confided in me about many harrowing aspects of their lives. I never crossed the line and shared my biggest problem with them—but now I wish I had.


October 30 • 2:00 PM

How Dark Money Got a Mining Company Everything It Wanted

An accidentally released court filing reveals how one company secretly gave money to a non-profit that helped get favorable mining legislation passed.


October 30 • 12:00 PM

The Halloween Industrial Complex

The scariest thing about Halloween might be just how seriously we take it. For this week’s holiday, Americans of all ages will spend more than $5 billion on disposable costumes and bite-size candy.


October 30 • 10:00 AM

Sky’s the Limit: The Case for Selling Air Rights

Lower taxes and debt, increased revenue for the city, and a much better use of space in already dense environments: Selling air rights and encouraging upward growth seem like no-brainers, but NIMBY resistance and philosophical barriers remain.


October 30 • 9:00 AM

Cycles of Fear and Bias in the Criminal Justice System

Exploring the psychological roots of racial disparity in U.S. prisons.


October 30 • 8:00 AM

How Do You Make a Living, Email Newsletter Writer?

Noah Davis talks to Wait But Why writer Tim Urban about the newsletter concept, the research process, and escaping “money-flushing toilet” status.



October 30 • 6:00 AM

Dreamers of the Carbon-Free Dream

Can California go full-renewable?


October 30 • 5:08 AM

We’re Not So Great at Rejecting Each Other

And it’s probably something we should work on.


October 30 • 4:00 AM

He’s Definitely a Liberal—Just Check Out His Brain Scan

New research finds political ideology can be easily determined by examining how one’s brain reacts to disgusting images.


October 29 • 4:00 PM

Should We Prosecute Climate Change Protesters Who Break the Law?

A conversation with Bristol County, Massachusetts, District Attorney Sam Sutter, who dropped steep charges against two climate change protesters.


October 29 • 2:23 PM

Innovation Geography: The Beginning of the End for Silicon Valley

Will a lack of affordable housing hinder the growth of creative start-ups?


October 29 • 2:00 PM

Trapped in the Tobacco Debt Trap

A refinance of Niagara County, New York’s tobacco bonds was good news—but for investors, not taxpayers.


October 29 • 12:00 PM

Purity and Self-Mutilation in Thailand

During the nine-day Phuket Vegetarian Festival, a group of chosen ones known as the mah song torture themselves in order to redirect bad luck and misfortune away from their communities and ensure a year of prosperity.


October 29 • 10:00 AM

Can Proposition 47 Solve California’s Problem With Mass Incarceration?

Reducing penalties for low-level felonies could be the next step in rolling back draconian sentencing laws and addressing the criminal justice system’s long legacy of racism.


October 29 • 9:00 AM

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.


October 29 • 8:00 AM

America’s Bathrooms Are a Total Failure

No matter which American bathroom is crowned in this year’s America’s Best Restroom contest, it will still have a host of terrible flaws.



October 29 • 6:00 AM

Tell Us What You Really Think

In politics, are we always just looking out for No. 1?


Follow us


Levels of Depression Could Be Evaluated Through Measurements of Acoustic Speech

Engineers find tell-tale signs in speech patterns of the depressed.

We’re Not So Great at Rejecting Each Other

And it's probably something we should work on.

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.

Incumbents, Pray for Rain

Come next Tuesday, rain could push voters toward safer, more predictable candidates.

Could Economics Benefit From Computer Science Thinking?

Computational complexity could offer new insight into old ideas in biology and, yes, even the dismal science.

The Big One

One town, Champlain, New York, was the source of nearly half the scams targeting small businesses in the United States last year. November/December 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.